Daily pill cuts body weight by up to 13% after 3 months in ... - NBC News
WEBSep 10, 2024 · The rate of weight loss with the experimental pill, called amycretin, appears to be more rapid than what’s seen for other drugs.
Daily pill cuts body weight by up to 13% after 3 months in early trial
WEBSep 11, 2024 · The rate of weight loss with the experimental pill, called amycretin, appears to be more rapid than what’s seen for other drugs.
Novo Nordisk’s new weight-loss pill Amycretin beats Wegovy in …
WEBAmycretin’s phase 1 trials show study participants lost 13.1% of their body weight after only 3 months. That’s over twice the amount of weight loss on Wegovy, which shows about 6% weight loss ...
Novo Nordisk experimental obesity pill has mild-to-moderate side ...
WEBSep 10, 2024 · Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects.
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
WEBSep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.
Novo Nordisk weight loss pill may be more effective than Wegovy …
WEBSep 10, 2024 · In a small Phase 1 trial, a 50-mg dose of the daily pill called amycretin, which activates receptors of both the amylin and GLP-1 hormones, led to 10.4% weight loss at about three months after...
Weight loss: Amycretin pill may be more effective than semaglutide
WEBSep 12, 2024 · Early findings from a phase 1 clinical trial first announced by the Danish company Novo Nordisk in March 2024, show that amycretin — an experimental drug they have developed to treat obesity —...
Novo Nordisk’s oral amycretin tops Wegovy in obesity trial
WEB1 day ago · Novo Nordisk has been boosted by data for an oral obesity therapy, amycretin, that was more effective than injectable Wegovy at reducing weight in a clinical trial.
Novo’s latest obesity pill spurs major weight loss in small trial
WEBMar 7, 2024 · Amycretin, a new oral drug from Novo Nordisk, helped obese people lose 13% of their body weight in three months, according to a small trial. The drug stimulates two gut hormones and may compete with injectable medicines like Wegovy and Zepbound.
New Ozempic-like pill reduces weight by 13%, study finds
WEBSep 11, 2024 · A new weight loss drug, amycretin, could rival Wegovy and Ozempic in its benefits for weight loss – showing promising results in trials.
Skip to content